Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 20/11/2019
SIETES contiene 92834 citas

<< anterior 21 a 40 de 141 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Naci H, Carter AW, Mossialos E. Why the drug development pipeline is not delivering better medicines. BMJ 2015;351:h5542. [Ref.ID 99639]
23. Cita con resumen
Haukoos JS, Lewis RJ. The propensity score. JAMA 2015;314:1637-8. [Ref.ID 99568]
24. Cita con resumen
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie S-A. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015;386:1147-55. [Ref.ID 99538]
25.Tiene citas relacionadas Cita con resumen
Redberg RF. Faster drug approvals are not always better and can be worse. JAMA Intern Med 2015;175:1398. [Ref.ID 99398]
26.Tiene citas relacionadas Cita con resumen
Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med 2015;175:1389-98. [Ref.ID 99397]
27. Cita con resumen
Young K. FDA advisers recommend first-in-class cholesterol-lowering meds. Journal Watch 2015:11 de junio. [Ref.ID 99172]
28. Cita con resumen
Gotzsche PC, Young AH, Crace J. Does long term use of psychiatric drugs cause more harm than good?. BMJ 2015;350:h2435. [Ref.ID 99101]
29.Tiene citas relacionadas Cita con resumen
Keaney Jr JF. Balancing the risks and benefits of dual platelet inhibition. N Engl J Med 2015;372:1854-6. [Ref.ID 99087]
30.Tiene citas relacionadas Cita con resumen
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800. [Ref.ID 99086]
31. Cita con resumen
Light DW, Lexchin J. Why do cancer drugs get such an easy ride?. BMJ 2015;350:h2068. [Ref.ID 98977]
32.Enlace a cita original Cita con resumen
Anónimo. The limitations and potential hazards of using surrogate markers . Therapeutics Initiative Evidence Based Drug Therapy 2014:octubre-diciembre. [Ref.ID 98447]
33. Cita con resumen
Anónimo. Adding ezetimibe to statin therapy may reduce CV events in high-risk patients with ACS. DIA Daily 2014:18 de noviembre. [Ref.ID 98333]
34.Tiene citas relacionadas Cita con resumen
Ebrahim S, Sohani ZN, Montoya L, Agarwal A, Thorlund K, Mills EJ, Ioannidis JPA. Reanalyses of randomized clinical trial data. JAMA 2014;312:1024-32. [Ref.ID 97952]
35.Tiene citas relacionadas Cita con resumen
Krumholz HM, Peterson ED. Open access to clinical trials data . JAMA 2014;312:1002-3. [Ref.ID 97950]
36. Cita con resumen
Spielmans GI, Kirsch I. Drug approval and drug effectiveness. Annual Review of Clinical Psychology 2014;214:741-66. [Ref.ID 97582]
37.Tiene citas relacionadas Cita con resumen
The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12. [Ref.ID 97194]
38. Cita con resumen
Cohen D. FDA official: "clinical trial system is broken". BMJ 2013;347:f6980. [Ref.ID 97177]
39.Tiene citas relacionadas Cita con resumen
Smith MEB, Totten A, Hickam DH, Fu R, Wasson N, Rahman B, Motu'apuaka M, Saha S. Pressure ulcer treatment strategies: a sytematic comparative effectiveness review. Ann Intern Med 2013;159:39-50. [Ref.ID 95856]
40.Tiene citas relacionadas Cita con resumen
Chou R, Dana T, Bougatsos C, Blazina I, Starmer AJ, Reitel K, Buckley DI. Pressure ulcer risk assessment and prevention: a systematic comparative effectiveness review. Ann Intern Med 2013;159:28-38. [Ref.ID 95855]
Seleccionar todas
<< anterior 21 a 40 de 141 siguiente >>